pharma · Metastatic Pancreatic Adenocarcinoma · Primary Biliary Cholangitis
Ipsen
Ipsen clinical programs — 27 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 70, Rue Balard, Paris, Île-de-France 75015, FR
- Employees
- 6,584
- Programs
- 27
- Drugs
- 36
- Patents
- 0
Ipsen projects
27 ClinicalTrials.gov programs sponsored by Ipsen.
Ipsen has 27 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
A4250-015
Ipsen
Alagille Syndrome
1 trial -
Botulinum toxin type A
Ipsen
Low Back Pain
1 trial -
CLIN-10200-458
Ipsen
Treatment of moderate to severe glabellar lines
1 trial -
CLIN-52120-463
Ipsen
Chronic migraine
1 trial -
CLIN-52120-464
Ipsen
Episodic Migraine
1 trial -
D-US-60010-001
Ipsen
Metastatic Pancreatic Adenocarcinoma
1 trial -
Odevixibat
Ipsen
Biliary Atresia
1 trial -
elafibranor, Elafibranor Placebo
Ipsen
Primary Biliary Cholangitis (PBC)
1 trial -
elafibranor, Placebo
Ipsen
Primary Biliary Cholangitis
1 trial -
elafibranor, Placebo tablet
Ipsen
Primary Biliary Cholangitis
1 trial -
CLIN-01194-450
Ipsen
Pancreatic Ductal Adenocarcinoma, Melanoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Solid tumors
1 trial -
CLIN-60190-453
Ipsen
Primary Sclerosing Cholangitis
1 trial -
D-FR-10200-001
Ipsen
Upper limb spasticity after stroke or traumatic brain injury
1 trial -
D-FR-10200-002
Ipsen
Treatment of Moderate to Severe Upper Facial Lines
1 trial -
F-FR-60000-023
Ipsen
Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma with a Clear-Cell Component Who Progressed After 1st Line Treatment with Checkpoint Inhibitors
1 trial -
IPN01195, IPN01195
Ipsen
Advanced Solid Tumour
1 trial -
IPN01203
Ipsen
Advanced Solid Tumor, Metastatic Solid Tumor
1 trial -
IPN10200
Ipsen
Episodic Migraine
1 trial -
IPN10200, IPN10200 placebo
Ipsen
Episodic Migraine Chronic Migraine
1 trial -
IPN60300
Ipsen
Advanced or metastatic solid tumours
1 trial -
Placebo capsule
Ipsen
Fibrodysplasia Ossificans Progressiva
1 trial -
Placebo of IPN10200, IPN10200
Ipsen
Cervical Dystonia
1 trial -
A Mass Balance Study of [14C]-IPN60250 in Healthy Adult Participants
Ipsen
Primary sclerosing cholangitis (PSC)
1 trial -
CLIN-60250-450
Ipsen
Not applicable
1 trial -
D-FR-60010-015
Ipsen
Metastatic Pancreatic Adenocarcinoma
1 trial -
CLIN-52120-452
Ipsen
Upper limb spasticity (ULS) of any aetiology (in US and France) or post- stroke ULS (in Canada)
1 trial -
Lanreotide Autogel 120 mg
Ipsen
Acromegaly
1 trial
Frequently asked questions
How many clinical projects does Ipsen have?
27 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.